American Society of Clinical Oncology (ASCO) 2008. 14. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, et al.: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26:3709–3714.PubMedCrossRef 15. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom find protocol A, Figg WD: ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008, 14:4543–4549.PubMedCrossRef 16. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure

Time Data. 2nd edition. New York: John Wiley and Sons; 1980. 17. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B: Pooled safety analysis of BAY 43–9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Sirolimus Eur J Cancer 2006, 42:548–556.PubMedCrossRef 18. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S: Arterial hypertension correlates with clinical outcome in colorectal

cancer patients treated with first-line bevacizumab. Ann Oncol 2009, 20:227–230.PubMedCrossRef 19. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219–225.PubMedCrossRef 20. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola PTK6 A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al.: BAY 43–9006 exhibits broad spectrum

oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099–7109.PubMedCrossRef 21. Segaert S, Chiritescu G, Lemmens L, Dumon K, Van Cutsem E, Tejpar S: Skin toxicities of targeted therapies. Eur J Cancer 2009,45(Suppl 1):295–308.PubMedCrossRef 22. Susman E: Rash correlates with tumour response after cetuximab. Lancet Oncol 2004, 5:647.PubMedCrossRef 23. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672–4678.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions LJ, TMS, BCE, CEB, and DKP carried out experiments; ECK, WLD, SK, RY, and GG treated the patients and collected the data for the study; LJ, TMS, DV, and DL conducted final statistical analysis; Study was conceived by TMS, RD, JV, and WDF; WDF provided financial support.